In veterinary compounding of oral powders and granules intended for top-dressing or mixing into semi-moist feed, spironolactone is embedded at strengths between 1 mg/g and 50 mg/g using a geometric dilution sequence in a 300 L double-ribbon blender operated at 25 rpm for 20 minutes after each addition. The carrier phase is a 1:1 mixture of lactose monohydrate and microcrystalline cellulose with a D50 between 80 µm and 150 µm; the micronized active substance is first screened through a 500 µm stainless-steel sieve to break loose agglomerates formed during storage. If direct blending is selected without granulation, the blend moisture content is controlled to ≤ 1.5% w/w by Karl Fischer titration because higher moisture reduces flow and promotes active-substance agglomeration on ribbon surfaces. Tap density is typically maintained between 0.45 g/mL and 0.65 g/mL; if bulk density falls below 0.40 g/mL, sachet fill volume exceeds target and static segregation increases. On production-scale rotary sachet packing lines, static charge on micronized spironolactone can transfer active substance to contact surfaces and cause yield losses; ionizing bars positioned after the filling station reduce the phenomenon. Uniformity of dosage units is assessed according to USP <905> with an acceptance value of ≤ 15.0.

When a granulated intermediate is required to reduce segregation, the dry blend is massed with a 5% w/v povidone K-30 solution at 8–12% w/w, passed through a 1.2 mm screen, and dried in a fluid-bed dryer at inlet air temperature 45°C with a dew point of ≤ 5°C until loss on drying is ≤ 2.0% w/w. Dried granules are sized through a 0.8 mm oscillating granulator and lubricated with 0.5% w/w sodium stearyl fumarate. The main production-scale failure mode is segregation of micronized spironolactone toward the bottom of the hopper during packaging; this is mitigated by reducing hopper drop height, using vibratory feeders with amplitude of ≤ 0.5 mm, and maintaining sieve fractions below 5% fines.

What Limits Content Uniformity in Low-Dose Capsule Blending?

Capsule strengths of 2 mg, 5 mg, and 10 mg filled into size 3 hard gelatin capsules present a content-uniformity constraint when the active fraction falls below 1.0% w/w. The micronized active substance is preblended with colloidal silicon dioxide at 0.25–0.5% w/w in a high-shear mixer at 1,000 rpm for 3 minutes to coat the fine particle surface and reduce interparticulate cohesion; the preblend is then diluted stepwise with pregelatinized starch and lactose monohydrate in a bin blender at 12 rpm. Flow is measured per USP <1174> using a 25 mm orifice; Hausner ratio values above 1.35 require the addition of 1.0% w/w sodium stearyl fumarate or 0.5% w/w magnesium stearate. Encapsulation is performed on a dosator-type capsule filler with a dosing disc speed of 60 cycles/min and dosator tip diameter of 6.0 mm; compaction force is adjusted to maintain fill weight variation at ≤ 3.0% RSD. Tamping pin machines are less suitable for this formulation because powder bed compression can generate density gradients along the pin, leading to weight variation above 4.0% RSD.

Dissolution testing per USP <711> Apparatus 1 at 100 rpm in 900 mL of 0.1 N hydrochloric acid containing 0.1% sodium lauryl sulfate is used to detect over-lubrication; over-mixing with magnesium stearate beyond 5 minutes at 25 rpm can reduce release at 30 minutes by more than 10 percentage points. Capsule shells are stored at 15–25°C and 35–55% RH because brittle fracture occurs below 30% RH and shell softening occurs above 65% RH.

Designing a Sterile Aqueous Suspension for Parenteral Administration

For parenteral use, the conversion of spironolactone into a sterile injectable suspension requires reducing the active substance to a D90 of ≤ 10 µm because the drug is practically insoluble in water with published aqueous solubility below 30 mg/L at 25°C. Particle size reduction is carried out by wet milling in a high-pressure homogenizer at 1,000–1,500 bar for 5–8 passes using a vehicle composed of water for injection, 0.5% w/v sodium carboxymethyl cellulose, 0.1% w/v polysorbate 80, and tonicity-adjusting sodium chloride. The suspending agent is hydrated at 60°C for 30 minutes and cooled to 25°C before active-substance addition to avoid viscosity drift. The final suspension has a Brookfield viscosity of 10–50 mPa·s at 25°C measured at 60 rpm with spindle LV-2; this range balances syringeability against sedimentation.

Sterilization is performed by terminal autoclaving at 121°C for 15 minutes. Heating can cause particle aggregation through Ostwald ripening and reduce free surfactant concentration; if the suspension shows a 25% increase in D90 after autoclaving, the batch is rejected. Vials are filled under aseptic conditions in an ISO 7 cleanroom with Grade B background per EU GMP Annex 1; fill volume is checked according to Ph. Eur. 2.9.17. Particulate matter is tested per USP <788>; for a small-volume injection the limits are 6,000 particles per container at ≥ 10 µm and 600 particles per container at ≥ 25 µm. Visible particulates are assessed per USP <790>.

Subcutaneous or intramuscular administration is typical for veterinary parenteral use; syringeability is evaluated using a standardized 21G needle and a texture analyzer at a crosshead speed of 100 mm/min. Published data for specific veterinary injectable spironolactone configurations is limited, so the extrusion force profile must be established during process validation rather than assumed from human products. The suspension is not suitable for intravenous injection because of the particulate nature of the dosage form. Storage at 2–8°C with intermittent gentle resuspension is recommended; freezing is prohibited.

When Micronized Spironolactone Is Dry-Blended for Direct Compression Tablets

Direct compression of spironolactone tablets is feasible when the active substance is micronized and the formulation contains sufficient brittle diluent to transmit force uniformly. The milled active substance with D50 of 2–5 µm and D90 of ≤ 15 µm per laser diffraction USP <429> is blended with microcrystalline cellulose, lactose monohydrate, crospovidone at 3–5% w/w, and magnesium stearate at 0.5–1.0% w/w in a 600 L bin blender at 12 rpm for 15 minutes. The order of addition is critical: the lubricant is added last and blended for 3 minutes to avoid shear-induced hydrophobic film formation on the active-substance surface. Over-lubrication beyond 5 minutes or at speeds above 15 rpm can extend disintegration time beyond 15 minutes and reduce dissolution Q at 30 minutes.

Tableting is performed on a rotary press with 8-station B-tooling, a force feeder speed of 30 rpm, and a turret speed of 40 rpm. Main compression force is set between 8 kN and 12 kN with precompression at 2–3 kN; tablet weight is monitored by an in-line force-displacement sensor. Dwell time at main compression is maintained above 10 ms to allow plastic deformation of microcrystalline cellulose and reduce elastic recovery; capping is observed when dwell time falls below 7 ms. Tablet breaking force is measured according to USP <1217> and is controlled at 60–90 N for a 200 mg tablet; friability is tested per USP <1216> with a limit of ≤ 1.0% w/w. The main production failure mode is picking on the upper punch face due to the high surface area of micronized spironolactone; this is mitigated by maintaining blend LOD at ≤ 2.0% w/w, using chromium nitride-coated punches, and installing compressed air jets at the punch tip to remove fines.

Dissolution is evaluated using USP <711> Apparatus 2 at 75 rpm in 900 mL of 0.1 N hydrochloric acid containing 0.1% sodium lauryl sulfate; the Q value at 60 minutes is typically set at not less than 75%. Content uniformity is assessed per USP <905> with acceptance value ≤ 15.0. Residual moisture is tested per USP <731>. Batch-to-batch variance in dissolution often correlates with particle size shifts: an increase in D90 above 15 µm can lower the 30-minute release by more than 10 percentage points; the milled active substance must be requalified by laser diffraction before each compression campaign.

Premix adsorption onto pregelatinized starch and maltodextrin is governed by carrier porosity

Veterinary premixes containing spironolactone for subsequent dilution into feed or oral liquid carriers are produced by adsorbing a micronized active-substance suspension onto a porous carrier in a horizontal ploughshare mixer. The active substance is first suspended in ethanol 96% or purified water at 10–20% w/w solids and sprayed at 2–3 kg/min onto pregelatinized starch and maltodextrin DE 15–20 in a 500 L mixer with chopper speed 1,500 rpm; the liquid addition continues until the carrier reaches an LOD of 8–10% w/w, after which vacuum drying at 40°C reduces residual moisture to ≤ 3.0% w/w. Residual ethanol is controlled per VICH GL18. Homogeneity is verified by HPLC with sampling at 10 points; the coefficient of variation should be ≤ 5.0%. Segregation in bulk bags is controlled by using carrier particles with D50 between 100 µm and 300 µm and avoiding fine particles below 45 µm.

When a solution dosage form is required for oral dosing, spironolactone is dissolved in a non-aqueous or co-solvent vehicle because aqueous solubility remains below 30 mg/L at 25°C. A concentrate at 5–20 mg/mL may be prepared using ethanol 96%, propylene glycol, and medium-chain triglycerides under low-shear agitation at 25–40°C. The solution is filtered through a 0.45 µm polypropylene filter prior to filling. The dominant stability risk is hydrolysis of the lactone ring; therefore the water content of the vehicle is maintained below 2.0% w/w by Karl Fischer titration, and the solution is packaged in amber glass bottles with nitrogen flushing. Stability stress testing should follow VICH GL3; published data for this specific veterinary solution configuration is limited. The concentrate is diluted with a sweetened aqueous vehicle immediately before oral administration and is not suitable for parenteral injection.